Results from expert surveys provide snapshots of our understanding of DME and shed light on where the 0.19-mg FAc implant stands in the current standard of care.
In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.
Current options, challenges in developing novel therapies.
A retina specialist shares his presentation from the 2023 ASRS Annual Meeting, which describes a study comparing the efficacy of 2 FDA-approved treatments for geographic atrophy based on an anchored matching-adjusted indirect comparison of phase 3 trial findings.
The company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”
Dr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.
This article is produced by Roche for healthcare professionals and is not intended to provide medical advice and/or treatment guidance. This website is not country-specific and therefore may contain information which is not applicable to your country.
Knowledge of tools used in data interpretation helps clinicians trust accuracy of findings.
While operating on a patient with chronic uveitis presents some challenges, there are a few pearls that may increase success.
Experts conclude the series with the hope that longer-acting agents will lead to better real-world outcomes for patients, mirroring clinical trial results and potentially preventing vision loss, especially in countries with limited access to healthcare.
Clinical benefit of complement inhibition has been demonstrated in clinical trials, but there are possible consequences to consider.
The approval marks the first new steroid on the ophthalmic market in more than 15 years.
Minimizing clinic visits, maximizing use of imaging modalities are key
The plan is intended to upgrade Vitagrus’ manufacturing process so that it can ultimately handle the global market supply.
Nonetheless,BDUMP remains a rare condition with fewer than 60 cases documented in literature.
A multifaceted evaluation that includes ultra-widefield imaging can reveal new information and influence treatment decisions.
Easier, more accessible functional studies have been made possible
When we discuss trial participation with patients, we stress that the goal of these studies is to obtain better visual outcomes and ease the treatment burden.
Electronic health records may be the future of practice management.
At this year's ARVO meeting, the Eye Care Network spoke with Daniel Saben PhD, who is being awarded the Cogan Lecture at this year's event.
At this year's ARVO meeting, the Eye Care Network spoke with Daniel Saben PhD, who is being awarded the Cogan Lecture at this year's event.
In an attempt to halt the progression of dry AMD and geographic atrophy, the use of high-resolution optical coherence tomography becomes pivotal.
Dr Charles Wykoff presents the results of a post hoc microperimetry analysis from the OAKS study demonstrating the effectiveness of pegcetacoplan in preserving visual function.
Closing out his discussion on the port delivery system in retinal diseases, Chirag Jhaveri, MD, considers how this approach has impacted the treatment landscape.
Physicians should consider hydrodynamic cavitation when performing this procedure.
A panel of retina specialists review new and emerging treatments in neovascular AMD and DME, highlighting high-dose aflibercept and KSI-301. Which emerging treatments are you most interested in?